crispr stock forecast zacks

The highest analyst price target. Stock Price Forecast.

Here S Why You Should Invest In Vertex Vrtx Stock Now Nasdaq

According to 33 analysts the average rating for CRSP stock is Buy The 12-month stock price forecast is 10989 which is an increase of 11662 from the.

. CRISPR Therapeutics Editas Medicine Sarepta Therapeutics and Beam Therapeutics are part of the Zacks top Analyst Blog. CRISPR Therapeutics AG - Hold. View CRISPR Therapeutics AG CRSP investment stock information.

The average price target for Crispr Therapeutics AG is 10150. Stock market data coverage from CNN. CRISPR Therapeutics stock forecasts are adjusted once.

View US markets world markets after hours trading quotes and other important stock market activity. According to 33 stock analysts the average 12-month stock price forecast for CRSP stock is 10989 which predicts an increase of 11662. On average 10 Wall Street analysts forecast CRSPs revenue for 2023 to be 21046638975 with the lowest CRSP revenue forecast at 263929543 and the highest CRSP revenue forecast at.

This is based on 13 Wall Streets Analysts 12-month price targets issued in the past 3 months. The CRISPR Therapeutics stock prediction results are shown below and presented as a graph table and text information. The 23 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 10000 with a high estimate of 22000 and a low estimate of.

Get the latest CRISPR Therapeutics AG CRSP detailed stock quotes stock data Real-Time ECN. Zacks proprietary data indicates that CRISPR Therapeutics AG is currently rated as a Zacks Rank 3 and we are expecting an inline return.

9nbydxtyvztdnm